Page 1,608«..1020..1,6071,6081,6091,610..1,6201,630..»

President of Senegal bucks anti-biotechnology pressure: ‘I am for the use of GMOs’ – Genetic Literacy Project

Posted: April 11, 2017 at 3:44 pm

President Macky Sall of Senegal has thrown his weight behind the adoption of agricultural biotechnology in the country.

.

President Sall made it clear that he supported the implementation of biotechnology in Senegal provided necessary measures to minimise risks were taken.

Macky Sall

I must say very clearly that I am for the use of GMOs based on the precautions taken and based on a dynamic regulation, otherwise we would be against progress. We must decide and step forward. We need to move forward because we have food security imperatives.

It is undeniable that GMOs can help meet current challenges, such as food insecurity, public health issues, natural resource conservation and climate change, he stressed.

We need serious thought to develop a strategy to maximise the use of GMOs, while mitigating the risks associated with them. That is why it is necessary to strengthen the National Biosafety Authority and to have an appropriate legal system combined with an efficient information system based on objective scientific values to assess the cost/benefit/risks ratio, he further stressed.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:GMOs: Senegal supports adoption of agric biotech

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Visit link:
President of Senegal bucks anti-biotechnology pressure: 'I am for the use of GMOs' - Genetic Literacy Project

Posted in Biotechnology | Comments Off on President of Senegal bucks anti-biotechnology pressure: ‘I am for the use of GMOs’ – Genetic Literacy Project

Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT – Post Analyst

Posted: April 11, 2017 at 3:44 pm

Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT
Post Analyst
Puma Biotechnology, Inc. (NASDAQ:PBYI) reached 85.92% versus a 1-year low price of $19.74. The stock was last seen 2.95% higher, reaching at $36.7 on Apr. 10, 2017. At recent session, the prices were hovering between $35.24 and $37.8. This company ...
Brokerages Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $0.00The Cerbat Gem
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$1.86 Per ShareBBNS
Puma Biotechnology, Inc. (NYSE:PBYI): Trader Update on the ...Midway Monitor
Sports Perspectives -NYSE Journal (press release)
all 15 news articles »

Continue reading here:
Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT - Post Analyst

Posted in Biotechnology | Comments Off on Puma Biotechnology, Inc. (PBYI) recently sold by insider CHARNAS ROBERT – Post Analyst

Brain cell therapy ‘promising’ for Parkinson’s disease – BBC News

Posted: April 11, 2017 at 3:41 pm


BBC News
Brain cell therapy 'promising' for Parkinson's disease
BBC News
Scientists believe they have found a way to treat and perhaps reverse Parkinson's disease, by making replacement cells to mend the damaged brain. They say human brain cells can be coaxed to take over the job of the ones that are destroyed in Parkinson's.
Cell Therapy 2.0: Reprogramming the Brain's Own Cells for Parkinson's TreatmentScientific American
Brain Cell Therapy Reverses Parkinson's-Like Symptoms In MiceHuffington Post UK
Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapyThe San Diego Union-Tribune
STAT -NHS Choices
all 67 news articles »

Visit link:
Brain cell therapy 'promising' for Parkinson's disease - BBC News

Posted in Cell Therapy | Comments Off on Brain cell therapy ‘promising’ for Parkinson’s disease – BBC News

GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote – Genetic Engineering & Biotechnology News

Posted: April 11, 2017 at 3:41 pm

GE Healthcare said today it has acquired Asymptote for an undisclosed price in a deal that the buyer said would strengthen its cell therapy portfolio with technologies designed to enable the cryopreservation of cellular materials.

Asymptote specializes in cryochain technology for sensitive cellular therapies, with the goal of significantly lowering the risk of contamination found in conventional processes.

The companys integrated suite of cryochain hardware, software, and consumables is designed to support cGMP and maintain the potency of cellular therapies by enabling ultra-low-temperature freezing during production, followed by thawing prior to administering to patients in clinical settings.

Asymptotes VIA FreezeTM range delivers liquid nitrogen-free cryopreservation, while the soon-to-be released VIA ThawTM series thaws deeply frozen cells using a dry conduction (water-free) process. The companys web-based my.Cryochain software platform is designed to support cell therapy companies as they scale their cryopreservation and thawing processes by synchronizing with the VIA Freeze and VIA Thaw products to standardize freezing and thawing programs across multiple sites, improving the visibility of remote processes.

Asymptotes high-quality offering takes us another step forward in our vision to industrialize cell therapy, and in providing reliable and high-quality services for our customers and patients around the world, Ger Brophy, Ph.D., general manager of GE Healthcares cell therapy business, said in a statement.

Added Asymptote founder and CEO John Morris, Ph.D.: The acquisition gives us the opportunity to reach a larger audience through the local specialist GE Cell Therapy team, provides us with a strong platform for our product launches, and allows us to significantly scale up our product development.

GE Healthcare reasons that demand for manufacturing and clinical delivery will increase as the cell therapy market grows and develops. The company cited statistics from the Alliance for Regenerative Medicine showing 804 clinical trials underway by the end of last year for cell therapies, as well as gene-modified cell therapies, gene therapies, and tissue-engineering therapies.

The acquisition of Asymptote is GE Healthcares latest move toward growing its cell therapy offerings. In July 2016, GE acquired Biosafe Group, a supplier of integrated cell bioprocessing systems, for an undisclosed sum. Three months earlier, GE Ventures teamed up with Mayo Clinic Ventures to launch Vitruvian Networks,a collaboration providing cloud-based software systems and manufacturing services for cell and gene therapies.

And in January 2016, GE Healthcare and the Government of Canada each committed C$20 million ($15 million) to launch the [emailprotected] Cell Therapy Centre of Excellence, created to promote new technologies for the production of cellular therapies in Toronto.

Read more:
GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote - Genetic Engineering & Biotechnology News

Posted in Cell Therapy | Comments Off on GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote – Genetic Engineering & Biotechnology News

Frequency Raises $32M in Series A to Develop Progenitor Cell Therapy for Hearing Loss – Genetic Engineering & Biotechnology News

Posted: April 11, 2017 at 3:41 pm

Frequency Therapeutics raised $32 million in a Series A financing to support development of its Progenitor Cell Activation (PCA) platform. The technology uses small molecules to trigger the division and differentiation of tissue-specific Lgr5+ progenitor cells and is initially being developed to generate new sensory cells in the inner ear as a treatment for noise-induced hearing loss. The Massachusetts-based firm says other potential applications of the platform could span skin disorders, muscle regeneration, and gastrointestinal diseases.

Frequencys Series A fundraising round was led by Cobro Ventures. Other investors included Morningside Ventures, Emigrant Capital, Korean Investment Partnership, Alexandria Real Estate Equities, and additional U.S. and international investors.

The PCA platform was developed by Robert Langer, Sc.D., and Jeffrey Karp, Ph.D., at the Massachusetts Institute of Technology (MIT), and Harvard Medical School. Frequency was established in 2015 to develop the platform for therapeutic indications and has an exclusive global license to relevant IP from MIT and Partners Healthcare. Bob Langer's and Jeff Karps vision is to gain much of the same effect as gene therapy and CRISPR by using small molecules, which we believe are safer and allow for easier delivery, stated Marc Cohen, co-founder of Cobro Ventures and chairman of Frequencys board of directors, which was established earlier this year. Our data is very compelling and we are excited to be moving to the clinic in the next 12 to 18 months.

Frequencys co-founders published in vitro research demonstrating use of their small-molecule approach to trigger the differentiation of Lgr5-expressing progenitor cells into sensory hair cells, in the February 21 issue of Cell Reports in a paper titled "Clonal Expansion of Lgr5-Positive Cells from Mammalian Cochlea and High-Purity Generation of Sensory Hair Cells."

Commenting on the initial, hearing loss indicaiton for the PCA platform, David Lucchino, Frequencys co-founder, president and CEO, added, With no effective therapy available, this presents an enormous market opportunity and we believe there is even broader potential in indications beyond hearing loss with the further development of the PCA platform.

Excerpt from:
Frequency Raises $32M in Series A to Develop Progenitor Cell Therapy for Hearing Loss - Genetic Engineering & Biotechnology News

Posted in Cell Therapy | Comments Off on Frequency Raises $32M in Series A to Develop Progenitor Cell Therapy for Hearing Loss – Genetic Engineering & Biotechnology News

Mesoblast takes off as cell therapy for heart failure passes interim test – FierceBiotech

Posted: April 11, 2017 at 3:41 pm

At the halfway point, a phase 3 trial of Mesoblast's off-the-shelf cell therapy for chronic heart failure is on track and should continue to completion, say advisers.

Shares in the Australian biotech hit a 12-month high on the update from the trial, which came after it enrolled 270 out of a planned total of 600 patients with moderate CHF andcruciallyrevealed no safety issues with Mesoblast's MPC-150-IM candidate.

The trial is still blinded so there is now way to tell if the therapy is having an effect, but it's a case of so far, so good, as the biotech looks ahead to completing the study next year.

The trial is seeing whether delivery of mesenchymal precursor cells (MPCs) via a catheter into the left ventricular heart muscle, to see if it can reduce non-fatal heart failure-related major adverse cardiac events (HF-MACE), such as death, needing a pacemaker implanted or undergoing a heart transplant.

Last year, Israeli drugmaker Teva returned rights to MPC-150-IM to Mesoblast, which it had inherited through its takeover of Cephalon. Mesoblast however decided to go it alone, a decision helped by a recent $40 million placement intended to help bring the CHF trial to fruition.

Analyst John Savin at Edison said in a recent note that the biotech may not have to wait for its own trial to complete before filing for U.S. approval. That could happen before the end of the year if a National Institutes of Health-sponsored trial of the therapy in end-stage heart failure patients hits the target.

The 159-patient NIH study is expected to complete enrolment in the first half andwith luckcould report top-line data before year-end, according to Savin. He reckons that could "lead to an application for accelerated approval" under the U.S. 21st Century Cures Act, which provides a speedy route to market for regenerative medicines.

"Passing this interim futility analysis for MPC-150-IM is an important milestone for Mesoblast and our cardiovascular disease program," commented CEO Silviu Itescu. "This validates our strategy and our prioritization of this valuable program." Analysts at Credit Suisse have previously suggested that that drug could be worth $4.1 billion in peak annual sales.

Mesoblast is not the only biotech looking at a stem cell approach to cardiovascular diseases. BioCardia is developing CardiAMP for CHF, reporting positive data from small phase 2 trial last year, while CardioCell presented mixed results on its candidate at the 2016 ESC Congress in Rome, and Celyad's C-Cure product failed to meet its objectives in its phase 3 CHART trial. Meanwhile, Belgium's TiGenix said recently its acute myocardial infarction therapy AlloCSC-01 hit its targets in a phase 1/2 trial.

The Australian biotech claimed an FDA green light to start trials of an MPC therapy given alongside corrective heart surgery for children with hypoplastic left heart syndrome (HLHS).

It's also in the build-up to a decision by option partner Mallinckrodt on its phase 3 MPC for chronic low back paindue in or before Septemberand a graft-versus-host disease (GVHD) candidate that should see pivotal results before year-end.

Follow this link:
Mesoblast takes off as cell therapy for heart failure passes interim test - FierceBiotech

Posted in Cell Therapy | Comments Off on Mesoblast takes off as cell therapy for heart failure passes interim test – FierceBiotech

Tackling Weight Loss and Diabetes With Video Chats – New York Times

Posted: April 11, 2017 at 3:40 pm


New York Times
Tackling Weight Loss and Diabetes With Video Chats
New York Times
About a year and a half ago, Robin Collier and her husband, Wayne, were like millions of other Americans: overweight and living with Type 2 diabetes. Despite multiple diets, the couple could not seem to lose much weight. Then Ms. Collier's doctor told ...

The rest is here:
Tackling Weight Loss and Diabetes With Video Chats - New York Times

Posted in Diabetes | Comments Off on Tackling Weight Loss and Diabetes With Video Chats – New York Times

These Smart Contacts Could Transform Diabetes Care – NBCNews.com

Posted: April 11, 2017 at 3:40 pm

This artist's rendition of high-tech contact lenses illustrates how transparent biosensors lenses could one day help people track their health. Jack Forkey/Oregon State University

Contact lenses packed with transparent sensors might one day help

These sugar-sensing lenses would give people a way to check their blood sugar levels without drawing blood, according to the scientists.

Typically, people with diabetes monitor their blood sugar by making a tiny prick in their fingertip to draw blood, and then using a small device to measure blood sugar levels.

Related:

But the proposed contact lenses could continuously monitor a person's

Devices that continuously monitor blood sugar levels are available, but they often require the insertion of electrodes under the skin, which can be painful, lead to skin irritation or infections, and must get replaced every several days. Contact lenses that could continuously and noninvasively monitor blood sugar levels could eliminate many of these problems, Herman said. And because

To make the blood-sugar-monitoring contact lens, the researchers used technology that was originally developed for electronic products. Specifically, the researchers tinkered with a material called indium gallium zinc oxide (IGZO), whose electronic properties have recently helped boost the image quality in smartphone, tablet and flat-panel displays while also saving power and improving touch-screen sensitivity.

"If you buy an iPhone or an Apple computer or a flat-screen TV nowadays, they use IGZO," Herman told Live Science. He presented his findings on April 4 at the national meeting of the American Chemical Society in San Francisco.

Related:

In the study, the researchers made contact lenses that included transparent sheets of transistors made with IGZO. To test if

The researchers found that the sensors could detect even very low concentrations of glucose, such as the levels typically found in tears.

In theory, more than 2,500 of these sensors could be embedded within a 1-square-millimeter patch of a contact lens, Herman said. And by using Wi-Fi or Bluetooth, the data collected by the lenses could be wirelessly transmitted to

But measuring blood sugar levels isn't the only potential use for

For example, sensors could be developed to measure a chemical called uric acid, which is found in higher levels in people with kidney disease or

"You could also look for molecules related to HIV or cancer," Herman said. "We want to see if there are good ways to catch cancer at very early stages, before it's a fatal disease."

Herman cautioned that the lenses are still in the very early stages of development. It could be a year or more before a prototype biosensing contact lens is ready for animal testing, he said. And tests in humans are even further off, he said.

Original article on

Editor's Recommendations

Follow NBC MACH on

The rest is here:
These Smart Contacts Could Transform Diabetes Care - NBCNews.com

Posted in Diabetes | Comments Off on These Smart Contacts Could Transform Diabetes Care – NBCNews.com

Arizona youth joins tribal officials to push for diabetes program funds – Navajo-Hopi Observer

Posted: April 11, 2017 at 3:40 pm

WASHINGTON Alton Villegas offered an unusual call to action March 29 for an 11-year-old boy: Destroy the ice cream man.

Alton is a member of the Salt River Pima-Maricopa Indian Community where nearly 10 percent of tribal members have Type 2 diabetes, including members of his family.

My mom and my grandma have diabetes, a lot of people in Salt River have diabetes, sadly, said Alton, who has been diagnosed as pre-diabetic. I think a lot of people have diabetes because they dont eat healthy and they dont exercise.

Thats what brought Alton to Washington March 29, where he was the youngest of six witnesses urging the Senate Indian Affairs Committee to reauthorize the Special Diabetes Program for Indians.

The program grants $150 million a year to about 300 programs that push diabetes prevention to tribes in 35 states, said Rear Adm. Chris Buchanan, acting director of the Indian Health Service. The program will end after September if it is not reauthorized.

Since the program began in 1997, tribal obesity rates have remained stubbornly high, said Sen. John Hoeven, R-North Dakota. He said Native Americans still have a greater chance of being diagnosed with Type 2 diabetes than any other group in America, and that diabetes is their fifth-leading cause of death.

But Hoeven, the committee chairman, also acknowledged at the hearing that the grants have helped lower diabetes and its complications, such as limb amputations, heart disease and kidney failure.

But theres still more work to be done.

The Salt River Pima-Maricopa Indian Community, like other grantees, uses its grant to educate families on the benefits of exercise and balanced diets, offering free family-oriented exercise classes and programs that promote healthy lifestyles.

After a 6-year-old on the reservation was diagnosed with Type 2 diabetes about three years ago, the tribal council began more screening at schools and found 52 percent of students were above the 95th percentile for weight.

When a screening showed that Alton was at risk for Type 2 diabetes, his family learned that he qualified for the Youth Wellness Camp in Prescott. Grant money from the federal program lets the tribe send at-risk youth to the camp.

I wanted to be healthier, so I went to camp, Alton said. I wanted to be able to help my mom and my grandma be healthier.

The healthy eating and daily exercise at camp helped Alton lose almost 16 pounds. His mother, Felicia Jimerson, said Altons new outlook on eating healthy and exercising is rubbing off on her three other kids.

Alton said that he tries to help his family and friends make healthier decisions, but they do not always listen.

I tell them all the time but not a lot of people care, cause that means they have to give up Hot Cheetos, said Alton, who has seen his friends buy at least four bags of the snack a day from the ice cream man.

We must destroy the ice cream man! Alton told the committee, to laughter.

Rachel Seepie, another member of the Salt River Pima-Maricopa Indian Community credits some of her success against her Type 2 diabetes to educational programs funded by the grant program.

After initially managing her condition with medication, she decided to turn instead to exercise and eating well. That has helped her lose weight, lower her blood sugar, decrease her average heart rate and complete two Iron Man triathlons, Seepie said.

Now, she is a senior fitness specialist with the Diabetes Service Program and teaches group exercise classes on the reservation.

My vision is that the Salt River Pima-Maricopa Indian Community and our members will learn how to become healthier, and they will have long full lives without Type 2 diabetes, Seepie told the committee.

Jimerson said after the hearing that can only happen if the grant program is reauthorized.

I think if they can continue that funding, its definitely going to make a change, she said. If that funding goes away, were in huge trouble.

See the rest here:
Arizona youth joins tribal officials to push for diabetes program funds - Navajo-Hopi Observer

Posted in Diabetes | Comments Off on Arizona youth joins tribal officials to push for diabetes program funds – Navajo-Hopi Observer

Those with diabetes have a special need to protect their vision – Buffalo News

Posted: April 11, 2017 at 3:40 pm

By Judith Whitehead - Contributing Writer

If you have diabetes Type 1-insulin dependent or Type 2-non-insulin dependent you may be at risk for eye disease.

It is imperative that those with diabetes get a dilated eye exam every year to check for eye health as well as overall health.

The eyes are the only place in the body that circulation can be viewed without doing an invasive procedure. Dilation paralyzes the focusing ability of the eye and therefore freezes the pupil open for a few hours. By doing simple dilation of the pupil, an eye doctor can view the retina and circulation. If the doctor suspects retinal damage or sees findings of diabetic degeneration, a simple angiogram can be done in an office setting to get even more details as to what is happening in the back of the eye.

Uncontrolled diabetes can endanger vision, Judith Whitehead says.

Elevated blood sugars can cause damage to eyesight that is not always reversible. At times, a special laser beam procedure can be done at an ophthalmologists office that can stop the damage and seal blood vessels that are leaking in the retina. It is a fairly quick procedure that leaves the vision blurry for a few hours. If the eye doctor finds damage in the retina, chances are the rest of the body may be at risk for damage as well.

People with diabetics need to take care of their health to maintain good eyesight. If diabetes is not controlled, it can cause havoc with the rest of the body as well. Good circulation is needed for a healthy body.

Maintain good eye health by performing a few simple tasks: See your doctor regularly; get blood work done every three to four months to get an overall picture of the blood sugar control, call a hemoglobin A1C test;be mindful of your diet; get regular exercise; and use your medications as directed.

Take care of your eyes. You only get one set.

Judith Whitehead, of East Amherst, is a certified ophthalmic technician.

email: refresh@buffnews.com

Originally posted here:
Those with diabetes have a special need to protect their vision - Buffalo News

Posted in Diabetes | Comments Off on Those with diabetes have a special need to protect their vision – Buffalo News

Page 1,608«..1020..1,6071,6081,6091,610..1,6201,630..»